Sharon Townson

CIK: 0001855689

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (50.0%)

Position reduction

Option Exercises (M)4 (33.3%)

Derivative conversions

Awards (A)2 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GLUE

Monte Rosa Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

GLUE
Monte Rosa Therapeutics, Inc.
Jul 6, 2026
Sale(S)
Direct
400 shares at avg. $24.13$10K
GLUE
Monte Rosa Therapeutics, Inc.
Jul 6, 2026
Exercise(M)
Direct
6K shares at avg. $6.14$37K
GLUE
Monte Rosa Therapeutics, Inc.
Jul 6, 2026
Sale(S)
Direct
5.6K shares at avg. $23.25$130K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 23, 2026
Exercise(M)
Direct
3K shares at avg. $6.14$18K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 23, 2026
Sale(S)
Direct
3K shares at avg. $20.00$60K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 17, 2026
Sale(S)
Direct
3K shares at avg. $19.00$57K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 17, 2026
Exercise(M)
Direct
3K shares at avg. $6.14$18K
GLUE
Monte Rosa Therapeutics, Inc.
May 29, 2026
Sale(S)
Direct
6K shares at avg. $19.87$119K
GLUE
Monte Rosa Therapeutics, Inc.
May 29, 2026
Exercise(M)
Direct
6K shares at avg. $6.14$37K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
3.2K shares at avg. $15.17$48K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
35K shares-
GLUE
Monte Rosa Therapeutics, Inc.
Jan 2, 2025
Award(A)
Direct
36K shares-

		Type	Shares	Price		Ownership
Jul 6, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	400	$24.13	$9,652	Direct
Jul 6, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	6,000	$6.14	$36,840	Direct
Jul 6, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	5,600	$23.25	$130,197	Direct
Jun 23, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	3,000	$6.14	$18,420	Direct
Jun 23, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	3,000	$20.00	$60,000	Direct
Jun 17, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	3,000	$19.00	$57,000	Direct
Jun 17, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	3,000	$6.14	$18,420	Direct
May 29, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	6,000	$19.87	$119,220	Direct
May 29, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	6,000	$6.14	$36,840	Direct
Jan 5, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	3,155	$15.17	$47,861	Direct
Jan 2, 2026	GLUE Monte Rosa Therapeutics, Inc.	Award(A)	35,000	-	$0	Direct
Jan 2, 2025	GLUE Monte Rosa Therapeutics, Inc.	Award(A)	36,000	-	$0	Direct

1-12 of 12 transactions

About Townson Sharon

Townson Sharon (SEC CIK 0001855689) files insider reports with the SEC as Chief Scientific Officer of Monte Rosa Therapeutics, Inc. (GLUE).

Signal8 holds 6 ownership filings by Townson Sharon, all Form 4s, filed between Jan 6, 2025 and Jul 7, 2026. Those filings report 12 transactions, from Jan 2, 2025 to Jul 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Townson Sharon's filings is in BOSTON, MA.

Recent filings by Townson Sharon

Jul 6, 2026: Open-market sale of GLUE shares (Form 4, code S).
Jul 6, 2026: Option exercise of GLUE shares (Form 4, code M).
Jul 6, 2026: Open-market sale of GLUE shares (Form 4, code S).
Jun 23, 2026: Option exercise of GLUE shares (Form 4, code M).
Jun 23, 2026: Open-market sale of GLUE shares (Form 4, code S).

Other insiders filing for Monte Rosa Therapeutics, Inc. (GLUE)

Bowen Matthew, Principal Accounting Officer
Warmuth Markus, President & CEO
Champoux Jennifer, Chief Operating Officer
Behbahani Ali, Director
Janku Filip, Chief Medical Officer
SCHIFF ANDREW N, Director

How to read Form 4 transaction codes